VTGN Live signaler | Maksimer profitt med Getagraph.com

SELG 112561 min ago

@ $5.09

Utstedt: 14 feb 2024 @ 15:30

Avkastning: -13.13%

Forrige signal: feb 12 - 19:37

Forrige signal: Kjøp

Avkastning: -0.97 %

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 20:29):

Stats
Dagens volum	250 698
Gjennomsnittsvolum	263 427
Markedsverdi	119.49M
EPS	$0 ( 2024-02-13 )
Neste inntjeningsdato	( $-0.340 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.490
ATR14	$0.0120 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Rotunno Mary L.	Buy	12 500	Stock Option (Right to Buy)
2024-03-04	Gin Jerry B	Buy	12 500	Stock Option (Right to Buy)
2024-03-04	Fitzpatrick Margaret M	Buy	12 500	Stock Option (Right to Buy)
2024-03-04	Curley Joanne	Buy	12 500	Stock Option (Right to Buy)
2024-03-04	Cunningham Ann Michelle	Buy	12 500	Stock Option (Right to Buy)

INSIDER POWER
98.62
Last 94 transactions
Buy: 11 348 392 \| Sell: 716 774

Volum Korrelasjon

Lang: 0.15 (neutral)

Kort: 0.54 (weak)

Signal:(41.855) Neutral

VistaGen Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
ADXN	0.836
SHYF	0.828
SRRK	0.827
FLUX	0.822
PRAX	0.821
LILAK	0.819
LILA	0.816
PXLW	0.816
TNXP	0.816
FOXA	0.805

10 Mest negative korrelasjoner
FEYE	-0.808

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

VistaGen Therapeutics Inc Korrelasjon - Valuta/Råvare

0.41
( neutral )

0.47
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.55
( weak negative )

-0.31
( neutral )

VistaGen Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$-227 300
Bruttogevinst:	$-737 100 (324.29 %)
EPS:	$-8.51

FY	2023
Omsetning:	$-227 300
Bruttogevinst:	$-737 100 (324.29 %)
EPS:	$-8.51

FY	2022
Omsetning:	$1.11M
Bruttogevinst:	$293 700 (26.49 %)
EPS:	$-7.24

FY	2021
Omsetning:	$1.09M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.208

Financial Reports:

No articles found.

VistaGen Therapeutics Inc

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.